Title	Response Rate
Number of Patients Screened	9
Number of Patients Enrolled	9
Number of Patients Evaluable for Toxicity	9
Number of Patients Evaluated for Efficacy	9
Evaluation Method	RECIST 1.1
Response Assessment CR	n = 0 (0%)
Response Assessment PR	n = 3 (33.3%)
Response Assessment SD	n = 2 (22.2%)
Response Assessment PD	n = 3 (33.3%)
Response Assessment OTHER	n = 1 (11.1%)
(Median) Duration Assessments PFS	7.3 months
(Median) Duration Assessments Duration of Treatment	9.1 weeks
Outcome Notes
Among three patients in cohort A, the ORR was 66%. Among six patients in cohort B who tumors harbored BRAF mutations with presumed or demonstrated low sensitivity to trametinib, ORR was 17%. ORR for defined class 2 mutations was 50% (one of two patients), 0% (zero of three patients) for known class 3 mutations, 50% (one of two patients) for unknown class, and 50% (one of two patients) for fusions. Of four patients with primary progressive disease, all had concurrent mutations in other key cancer cell signaling pathways, including KIT (n = 2), NF2 and PTEN, and MET. Of five patients with response or stable disease, three had no other concurrent mutations identified, although two did have KRAS G12V and NF1 mutations, respectively. Of two patients with mucosal melanoma, one had durable stable disease, and one had primary progression. Among all patients, median PFS was 7.3 months. Among three responders, one had progression‐free intervals of 19.3 months, 8.3 months (ongoing and changed to immunotherapy), and 1.8 months (ongoing and discontinued therapy for side effects). Two additional patients had stable disease lasting 22.3 and 7.3 months, respectively.